Alessandro D. Santin MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., University of Brescia School of Medicine (1989)
  • Resident, University of Brescia School of Medicine , Obstetrics & Gynecology (1990 - 1993)
  • Fellow, University of Arkansas for Medical Sciences , Gynecology Oncology (1995 - 2000)
  • Fellow, University of California - Irvine Medical Center , Gynecology Oncology (1993 - 1995)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Cancer of the ovary, uterus, vagina, cervix and vulva; Intraperitoneal chemotherapy; Tumor immunology and immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in Gynecologic Oncology


Cancers Treated

Cervix, Gestational Trophoblastic Neoplasia, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Obstetrics & Gynecology, FB (1993)

Clinical Trials

ConditionsStudy Title
Corpus UteriRandomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors
Other Female GenitalA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

More Clinical Trials...

Edit Profile